Tim Kelly joined Foundation Medicine in January 2019 as Chief Financial Officer and a member of the Executive Team. He brings two decades of healthcare experience in finance, strategic planning, and employee engagement and team development. In his role as CFO, Tim will lead the Finance team, providing overall direction and leadership to the company’s breadth of financial functions, which include accounting and finance, billing and reimbursement, asset management, and financial planning and analysis.
Prior to joining Foundation Medicine, Tim served in roles of increasing responsibility at Roche Genentech for the past 15 years. Tim joined Genentech as a principal financial analyst for product operations, then moved into the role of senior finance manager for supply chain strategic planning, with responsibilities that included business planning for Genentech’s Product Operations division. In 2007 he transitioned to director of product development finance where he led a finance team that collaborated closely with medical and research and development (R&D) teams to support the development needs of the business. In 2009, Tim moved to portfolio management, where he oversaw the global sales forecasting for the Pharma organization. In 2013, Tim was promoted to head of Group Planning and Special Projects, where he led the business plan for the Roche Group and contributed to the Group’s work on R&D productivity and sustainability. In 2016, Tim transitioned into his most recent role as finance and corporate services director for Roche Products Limited UK, focusing on creating and implementing strategic improvements to the UK business and enabling the team to deliver strong business and operating results and importantly, significant patient impact.
Tim began his career in consulting with Arthur Andersen in the litigation consulting practice and marchFIRST, an internet-focused strategy consulting firm, after earning his MBA at Columbia Business School. He also holds a Bachelor of Arts in Economics from the College of William and Mary.